Date: 2-5 April 2019
Venue: Bournemouth International Centre, UK
Oral Research Presentations: Session 2 (7–15)
Abstract O07 - The role of Raltegravir alone or combined with Lamivudine as PrEP: a phase 2 randomised controlled clinical trial
Julie Fox, Guys and St Thomas’ NHS Trust
Abstract O08 - Pharmacokinetics (PK) of bictegravir (BIC) in combination with polyvalent cation containing (PVCC) antacids and supplements
Samuel Kabagambe, Gilead Sciences
Abstract O09 - High level of pre-existing NRTI resistance prior to switching to B/F/TAF (Study 4030)
Leena Sathia, Gilead Sciences
Abstract O10 - Long-active cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results
Chloe Orkin, Queen Mary University
Abstract O11 - The impact of vorinostat & therapeutic vaccine on gut HIV DNA – the RIVER gut study
John Thornhill, Imperial College London
Abstract O12 - The effect of time to viral suppression at primary HIV infection on long term immunological recovery: results from the HEATHER cohort
Julianne Lwanga, Guy’s & St. Thomas’ NHS Foundation Trust
Abstract O13 - Discontinuations & virologic response in late presenters with insti -or pi-based art
Jessica Doctor, Guy’s and St Thomas’s Hospital
Abstract O14 - Sustained HIV-1 remission following CCR5Δ32/Δ32 allogeneic haematopoietic stem cell transplantation
Laura Waters, Mortimer Market Centre
Abstract O15 - Safety of tenofovir alafenamide (TAF) in patients with a history of proximal renal tubulopathy on tenofovir disoproxil fumarate (TDF)
Frank Post, King’s College London
BHIVA Plenary Session 2: Keynote Lecture
New Challenges for ART programmes
Dr Angela Obasi, Liverpool School of Tropical Medicine
Click here to go back to all presentations.